|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FTO |
Gene summary for FTO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FTO | Gene ID | 79068 |
| Gene name | FTO alpha-ketoglutarate dependent dioxygenase | |
| Gene Alias | ALKBH9 | |
| Cytomap | 16q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | B3KU60 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79068 | FTO | CCI_1 | Human | Cervix | CC | 1.46e-06 | 7.90e-01 | 0.528 |
| 79068 | FTO | CCI_2 | Human | Cervix | CC | 3.07e-02 | 5.72e-01 | 0.5249 |
| 79068 | FTO | CCI_3 | Human | Cervix | CC | 6.36e-12 | 7.49e-01 | 0.516 |
| 79068 | FTO | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.69e-13 | -4.22e-01 | 0.0155 |
| 79068 | FTO | HTA11_696_2000001011 | Human | Colorectum | AD | 3.12e-03 | -2.62e-01 | -0.1464 |
| 79068 | FTO | HTA11_866_2000001011 | Human | Colorectum | AD | 1.92e-04 | -3.28e-01 | -0.1001 |
| 79068 | FTO | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.03e-03 | -6.56e-01 | -0.2061 |
| 79068 | FTO | HTA11_866_3004761011 | Human | Colorectum | AD | 1.26e-05 | -4.47e-01 | 0.096 |
| 79068 | FTO | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.55e-02 | -2.66e-01 | 0.0674 |
| 79068 | FTO | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.67e-09 | -4.28e-01 | 0.294 |
| 79068 | FTO | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.13e-13 | -5.19e-01 | 0.3005 |
| 79068 | FTO | F007 | Human | Colorectum | FAP | 1.68e-03 | -2.24e-01 | 0.1176 |
| 79068 | FTO | A001-C-207 | Human | Colorectum | FAP | 7.55e-06 | -3.41e-01 | 0.1278 |
| 79068 | FTO | A015-C-203 | Human | Colorectum | FAP | 1.26e-39 | -5.08e-01 | -0.1294 |
| 79068 | FTO | A015-C-204 | Human | Colorectum | FAP | 2.92e-11 | -4.19e-01 | -0.0228 |
| 79068 | FTO | A014-C-040 | Human | Colorectum | FAP | 3.24e-05 | -5.00e-01 | -0.1184 |
| 79068 | FTO | A002-C-201 | Human | Colorectum | FAP | 4.55e-19 | -5.12e-01 | 0.0324 |
| 79068 | FTO | A002-C-203 | Human | Colorectum | FAP | 6.87e-05 | -1.40e-01 | 0.2786 |
| 79068 | FTO | A001-C-119 | Human | Colorectum | FAP | 2.38e-08 | -4.95e-01 | -0.1557 |
| 79068 | FTO | A001-C-108 | Human | Colorectum | FAP | 3.83e-26 | -4.26e-01 | -0.0272 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00610143 | Colorectum | CRC | positive regulation of mRNA catabolic process | 25/2078 | 87/18723 | 5.27e-06 | 2.12e-04 | 25 |
| GO:00486383 | Colorectum | CRC | regulation of developmental growth | 64/2078 | 330/18723 | 5.74e-06 | 2.26e-04 | 64 |
| GO:19033133 | Colorectum | CRC | positive regulation of mRNA metabolic process | 30/2078 | 118/18723 | 9.83e-06 | 3.31e-04 | 30 |
| GO:00064175 | Colorectum | CRC | regulation of translation | 82/2078 | 468/18723 | 1.79e-05 | 5.40e-04 | 82 |
| GO:00346555 | Colorectum | CRC | nucleobase-containing compound catabolic process | 73/2078 | 407/18723 | 2.28e-05 | 6.57e-04 | 73 |
| GO:00611573 | Colorectum | CRC | mRNA destabilization | 23/2078 | 84/18723 | 2.93e-05 | 7.73e-04 | 23 |
| GO:00442705 | Colorectum | CRC | cellular nitrogen compound catabolic process | 78/2078 | 451/18723 | 4.48e-05 | 1.07e-03 | 78 |
| GO:00467005 | Colorectum | CRC | heterocycle catabolic process | 77/2078 | 445/18723 | 4.92e-05 | 1.14e-03 | 77 |
| GO:00507793 | Colorectum | CRC | RNA destabilization | 23/2078 | 88/18723 | 6.51e-05 | 1.42e-03 | 23 |
| GO:00194395 | Colorectum | CRC | aromatic compound catabolic process | 77/2078 | 467/18723 | 2.42e-04 | 4.00e-03 | 77 |
| GO:19013615 | Colorectum | CRC | organic cyclic compound catabolic process | 80/2078 | 495/18723 | 3.52e-04 | 5.34e-03 | 80 |
| GO:00016591 | Colorectum | CRC | temperature homeostasis | 32/2078 | 174/18723 | 2.81e-03 | 2.55e-02 | 32 |
| GO:00342492 | Colorectum | CRC | negative regulation of cellular amide metabolic process | 45/2078 | 273/18723 | 4.35e-03 | 3.47e-02 | 45 |
| GO:00108763 | Colorectum | CRC | lipid localization | 68/2078 | 448/18723 | 4.60e-03 | 3.58e-02 | 68 |
| GO:00171482 | Colorectum | CRC | negative regulation of translation | 41/2078 | 245/18723 | 4.82e-03 | 3.72e-02 | 41 |
| GO:00352642 | Colorectum | CRC | multicellular organism growth | 25/2078 | 132/18723 | 5.21e-03 | 3.97e-02 | 25 |
| GO:00400141 | Colorectum | CRC | regulation of multicellular organism growth | 14/2078 | 61/18723 | 6.06e-03 | 4.46e-02 | 14 |
| GO:190331110 | Endometrium | AEH | regulation of mRNA metabolic process | 77/2100 | 288/18723 | 1.69e-13 | 4.40e-11 | 77 |
| GO:000989616 | Endometrium | AEH | positive regulation of catabolic process | 104/2100 | 492/18723 | 9.38e-11 | 1.10e-08 | 104 |
| GO:003133116 | Endometrium | AEH | positive regulation of cellular catabolic process | 91/2100 | 427/18723 | 9.15e-10 | 8.31e-08 | 91 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FTO | SNV | Missense_Mutation | rs577569584 | c.559G>A | p.Gly187Arg | p.G187R | Q9C0B1 | protein_coding | tolerated(0.52) | benign(0.033) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| FTO | SNV | Missense_Mutation | c.1180N>A | p.Asp394Asn | p.D394N | Q9C0B1 | protein_coding | tolerated(0.1) | probably_damaging(0.946) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FTO | SNV | Missense_Mutation | novel | c.584N>T | p.Ser195Ile | p.S195I | Q9C0B1 | protein_coding | tolerated(0.07) | possibly_damaging(0.785) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| FTO | SNV | Missense_Mutation | c.574N>C | p.Asp192His | p.D192H | Q9C0B1 | protein_coding | tolerated(0.07) | possibly_damaging(0.77) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| FTO | insertion | Frame_Shift_Ins | novel | c.582_583insTCTGCTCACTCCGGTATCTCGCATCCTCATTGGTA | p.Arg196AlafsTer11 | p.R196Afs*11 | Q9C0B1 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| FTO | deletion | Frame_Shift_Del | novel | c.865delC | p.Leu289PhefsTer68 | p.L289Ffs*68 | Q9C0B1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FTO | SNV | Missense_Mutation | c.1042G>A | p.Asp348Asn | p.D348N | Q9C0B1 | protein_coding | tolerated(0.11) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FTO | SNV | Missense_Mutation | novel | c.1132N>A | p.Trp378Arg | p.W378R | Q9C0B1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| FTO | SNV | Missense_Mutation | c.1180G>A | p.Asp394Asn | p.D394N | Q9C0B1 | protein_coding | tolerated(0.1) | probably_damaging(0.946) | TCGA-EK-A2RM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FTO | SNV | Missense_Mutation | rs577569584 | c.559N>A | p.Gly187Arg | p.G187R | Q9C0B1 | protein_coding | tolerated(0.52) | benign(0.033) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 79068 | FTO | ENZYME | interferon alfa-2b, recombinant | 25367448 | ||
| 79068 | FTO | ENZYME | mercaptopurine | MERCAPTOPURINE | 27558924 | |
| 79068 | FTO | ENZYME | azathioprine | AZATHIOPRINE | 27558924 | |
| 79068 | FTO | ENZYME | interferon alfa-2a, recombinant | 25367448 | ||
| 79068 | FTO | ENZYME | ribavirin | RIBAVIRIN | 25367448 | |
| 79068 | FTO | ENZYME | atenolol | ATENOLOL | ||
| 79068 | FTO | ENZYME | ethanol | ALCOHOL | 32451486 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |